Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Run-In Period Inclusion Criteria:~* Males or females aged 12 years or older.~* A clinical diagnosis of hereditary angioedema type I or II.~* Hereditary angioedema attacks over a consecutive 2-month period that required acute treatment, medical attention, or caused significant functional impairment.~* For subjects who have used oral therapy for prophylaxis against HAE attacks within 3 months of Screening: use of a stable regimen within 3 months of Screening, with no plans to change.~Eligibility Criteria for Entering Treatment Period 1:~* Laboratory confirmation of type I or type II hereditary angioedema, including C1-esterase inhibitor functional activity less than 50% AND C4 antigen level below the laboratory reference range.~* No clinically significant abnormalities as assessed using laboratory parameters.~* During participation in the run-in period, subjects must have experienced hereditary angioedema attacks that required acute treatment, required medical attention, or caused significant functional impairment.~Exclusion Criteria:~Run-In Period Exclusion Criteria:~* History of clinical significant arterial or venous thrombosis, or current history of a clinically significant prothrombotic risk.~* Incurable malignancies at screening.~* Any clinical condition that will interfere with the evaluation of C1-esterase inhibitor therapy.~* Clinically significant history of poor response to C1-esterase therapy for the management of hereditary angioedema.~* Receiving therapy prohibited by the protocol, including medications for hereditary angioedema prophylaxis.~* Female subjects who started taking or changed dose of any hormonal contraceptive regimen or hormone replacement therapy (i.e., estrogen/progesterone-containing products) within 3 months prior to the screening visit.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Higher-volume placebo, then low-volume C1-esterase inhibitor (Type: EXPERIMENTAL): A higher-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks, then a low-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks.
- Low-volume C1-esterase inhibitor, then higher-volume placebo (Type: EXPERIMENTAL): A low-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks, then a higher-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks.
- Low-volume placebo, then higher-volume C1-esterase inhibitor (Type: EXPERIMENTAL): A low-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks then a higher-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks.
- Higher-volume C1-esterase inhibitor, then low-volume placebo (Type: EXPERIMENTAL): A higher-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks, then a low-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete